Hormonal manipulation of benign prostatic hyperplasia

Ferenc G. Rick, Seyed H. Saadat, Luca Szalontay, Norman L. Block, Amir Kazzazi, Bob Djavan, Andrew V. Schally

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

PURPOSE OF REVIEW: We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH). The latest treatment findings with 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride, refined indications, efficacy, and safety are discussed and compared. We also discuss potential new 5-ARIs and other hormonal treatments. RECENT FINDINGS: Finasteride and dutasteride have equal efficacy and safety for the treatment and prevention of progression of BPH. 5-ARIs are especially recommended for prostates greater than 40 ml and PSA greater than 1.5 ng/ml. Combination therapy is the treatment of choice in these patients, but with prostate volume greater than 58 ml or International Prostate Symptom Score of at least 20, combinations have no advantage over 5-ARI monotherapy. Updates on the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed. Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink experimentally enlarged prostates alone or in combination with LHRH antagonists. SUMMARY: New 5-ARIs seem to be the promising agents that need further study. Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate volume. Recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors. The adverse effects of 5ARIs encourage alternative therapy.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalCurrent opinion in urology
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2013

Keywords

  • 5-alpha reductase inhibitor
  • benign prostatic hyperplasia
  • gonadotropin-releasing hormone
  • growth hormone-releasing hormone
  • lower urinary tract symptoms
  • luteinizing hormone-releasing hormone

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Hormonal manipulation of benign prostatic hyperplasia'. Together they form a unique fingerprint.

  • Cite this

    Rick, F. G., Saadat, S. H., Szalontay, L., Block, N. L., Kazzazi, A., Djavan, B., & Schally, A. V. (2013). Hormonal manipulation of benign prostatic hyperplasia. Current opinion in urology, 23(1), 17-24. https://doi.org/10.1097/MOU.0b013e32835abd18